Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Medrogestone”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

125 records · Page 7Linked to original sources
PubMed1982

The importance of gestagen, tamoxifen and steroid receptors in the therapy of endometrial cancer. Report of an experiment.

Six human endometrial cancers in different clinical stages were xenotransplanted into thymusaplastic nude mice. Estrogen and progesterone receptors in the tumor tissue were determined in each case. Two carcinomas with both estrogen and progesterone receptors showed a better clinical course and grew more slowly in nude mice than the four carcinomas with no receptors at all. Treatment with the antiestrogen Tamoxifen in the carcinoma with positive estrogen receptors showed a significant growth retardation compared with the control group. Estrogen treatment gave accelerated growth, whereas gestagen treatment showed no significant effect. The progesterone receptor content of the receptor-positive tumor tissue might have been too small. None of the four receptor-negative carcinomas showed any influence of tumor growth during endocrine therapy. The results demonstrate the importance of receptor determination as a prognostic sign and, further, allow the endocrine therapy of endometrial carcinomas to be complemented with Tamoxifen in estrogen-receptor-positive tumor tissue.

Aged↗
PubMed1975

[Comparison of the results of radio gold therapy, cobalt 60 teletherapy and chemotherapy in 330 ovarian neoplasms].

From 1960 to 1972, 276 out of 330 cases of ovarian cancer were treated by different techniques of postoperative radiation therapy; 54 advanced cases underwent prospective chemotherapy. Radiogold intraabdominally administered (190 to 300 mCi), telecobalt (5000 rd) or the combination of radiogold and telecobalt was chosen for postoperative radiation therapy. Cyclophosphamide (Endoxan), prednisolone, and gestagenes (Prothil) were given as a long-term chemotherapy. The most successful technique of radiation therapy is confronted with long-term chemotherapy after three years (five years) of survival: Stage I a, b, c: Radiogold = 91.7% (66.7%), chemotherapy (only I c) = 100%. Stage II a, b: Radiogold + telecobalt = 47% (35%), chemotherapy = 85%. Stage III: Radiogold + telecobalt = 25% (0%), chemotherapy = 52%. Stage IV: Radiotherapy = 0%, chemotherapy = 25%. The absolute five-year survival without chemotherapy amounted to 23%. The mortality curve under chemotherapy shows a four-year survival rate of 88%, if tumor cells had been detected microscopically (ascites, omentum), but of only 30% after macroscopical verification of the tumor. Therefore, the maximally possible partial resection of the tumor is recommended in inoperable stages before the beginning of chemotherapy. "Prophylactic" long-term chemotherapy following macroscopically complete surgical treatment is recommended, whenever microscopical spread of tumor cells appears to be possible. In inoperable stages, chemotherapy ought to be applied prior to radiation therapy. In stages I a, b, c, and II a, postoperative irradiation with radiogold (100 mCi) and in stage II b additionally radiation teletherapy of the pelvis (6000 rd) is recommended.

Cobalt Radioisotopes↗
PubMed2002

[Tibolone].

INDIRECT MECHANISM OF ACTION: Tibolone (OD 14) is the precursor of its active principles that are its metabolites: 3 alpha and 3 beta hydroxylated derivatives. In vivo, the latter behave like estrogens. Certain tissues (liver, endometrium) may metabolize the 3 beta ol derivative into the delta 4 isomer with progestagenic and androgenic activity. The metabolism of the product in other tissues such as the breast and brain is unknown. ACTIVITY: At the dose of 2.5 mg/day, the product expresses an estrogen activity equivalent to that observed with classical doses of estrogens in the brain, genito-urinary tract, vascular endothelium and bone. In the brain and muscle, it also has a slightly androgenic effect and in the breast an antiestrogenic effect. ON METABOLIC LEVEL: The product acts like a minor androgen (lowering triglycerides and HDL cholesterol without interfering in the cholesterol cell flow) and it stimulates fibrinolysis. ON CLINICAL LEVEL: Tibolone treats the symptoms of estrogen privation and protects against bone loss, without inducing bleeding or mastodynia. There is a lack of large epidemiological studies on prevention of fracture risks, cardiovascular effects and breast. Tolerance in the population studied was excellent (healthy population). However, tolerance remains to be assessed in particular sub-groups (populations at risk of certains pathologies).

Adult↗
PubMedDate not supplied

Effects of hormone replacement therapy on the main fatty acids of serum and phospholipids of postmenopausal women.

BACKGROUND: The anti-atherosclerotic effects of hormone replacement therapy (HRT) in postmenopausal women are partly mediated by improvement of the lipid and lipoprotein profiles. The present study aimed to investigate the effects of HRT on the main fatty acids of serum and phospholipids in postmenopausal women. PATIENTS AND METHODS: Serum samples of two groups of postmenopausal women, receiving either single oestrogen or in combination with progestogens, were analysed before and after a 6- month treatment period. RESULTS: Of the main serum fatty acids, there was a significant reduction in palmitic (p < 0.05) and arachidonic acids (p < 0.001), followed by an increase in oleic (p < 0.05) and linoleic acids (p < 0.05) in postmenopausal women receiving HRT compared to single oestrogen. The main fatty acids in phospholipids showed a similar pattern in those women. CONCLUSION: The above results demonstrate the beneficial effects of HRT in reducing the risk of cardiovascular disease through modification of the fatty acid profiles of postmenopausal women.

Estrogen Replacement Therapy↗
PubMed1985

Effects of progestational agents in treatment of endometrial carcinoma.

Progestational agents induced an objective response in 11.2% of 155 patients with advanced primary or recurrent endometrial carcinoma. Response rates decreased with decreasing tumor differentiation from 40% with Broders grade 1 lesions to 17.5, 2.4, and 0%, respectively, with grades 2, 3, and 4. 17 alpha-Hydroxyprogesterone caproate (Delalutin), 6,17 alpha-dimethyl-6-dehydroprogesterone (Colprone), and 6-methyl-6-dehydroprogesterone acetate (Megace) were the progestogens used; there was no significant advantage for any one agent. Overall, survival after initiation of hormone therapy was 40% at one year, 19% at two years, and 8% at five years. Survival was highly dependent on the degree of tissue differentiation (P less than .001) and was influenced significantly by the estimated tumor volume at the start of therapy (P less than .01) and by the time interval from primary treatment to the beginning of hormone therapy (P less than .01).

17 alpha-Hydroxyprogesterone Caproate↗
PubMed1981

Psycho-endocrine differences and correlations in symptomatic and asymptomatic climacteric women - the possible role of prolactin.

The hormonal and psychological profiles of 23 women with the climacteric syndrome were compared with those of 10 asymptomatic postmenopausal women. Statistical analysis of the results of this prospective study revealed significant differences in luteinizing hormone, oestradiol and prolactin values. Interesting correlations linking the clinical, hormonal and psychological parameters are presented and discussed. A hypothesis is advanced to explain the elevated levels of serum prolactin in asymptomatic postmenopausal women. A psycho-endocrine profile of the symptomatic climacteric women is presented.

Adult↗
PubMed1995

Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way.

Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end of cycle 3 and cycle 13. Secondly, in 15 mothers and 23 daughters using oral contraceptives (OC) containing 30-50 micrograms ethinyl estradiol (EE) daily the mean HRG level was 14% and 24% lower than in a group of 144 mothers and 134 daughters not taking oral contraceptives, respectively (p < 0.05). Finally, in 11 excessively tall prepuberal girls who received 300 micrograms EE daily to reduce their final height the mean plasma HRG levels were decreased by 68% (p < 0.005). The effect of progestogens administered during low-dose and high-dose estrogen therapy appeared to be minor. The results from these three studies indicate that estrogens reduce plasma HRG levels in a dose-dependent way.

Adolescent↗